Trial Profile
Phase II trial of Lenvatinib in patients with metastatic or recurrent thymic carcinoma;REMORA trial (NCCH1508,REMORA trial)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- Acronyms REMORA trial
- 01 Apr 2021 Planned End Date changed from 30 Apr 2021 to 30 Jul 2021.
- 01 Jun 2020 Primary endpoint has been met. (Response rate; Central Review)
- 01 Jun 2020 Results published in the Lancet Oncology